✨ Free AI Report
Azitra, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Azitra, Inc.
Company Research

Azitra, Inc.: Business Overview, Financials & Competitive Analysis

Azitra, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage precision dermatology biotech with novel bacterial therapeutic platform and strategic pharma validation, suitable only for venture-stage risk appetites. Early-stage biotech with differentiated live biotherapeutic platform and pharma partnership support, but minimal employee base (12 FTE) and pre-revenue stage creates execution and funding risk. Clinical progress and Bayer alignment are.

What is Azitra, Inc.'s industry? Azitra, Inc. (azitrainc.com) operates in Biotechnology - Live Biotherapeutics / Dermatology. AskCyborg classifies Azitra, Inc. under Biotechnology - Live Biotherapeutics / Dermatology in its company registry.

Azitra is an early-stage clinical biopharmaceutical company developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company represents a fo...

4/ 10Mixed

Cyborg Score thesis

Early-stage precision dermatology biotech with novel bacterial therapeutic platform and strategic pharma validation, suitable...

Read the full analyst-debate transcript →
Industry Biotechnology - Live Biotherapeutics / Dermatology
2 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Azitra, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Azitra, Inc.

AskCyborg analysts argue the bull and bear cases for Azitra, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Azitra, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Azitra, Inc. Overview

Pro stress-test →

Azitra is an early-stage clinical biopharmaceutical company developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company represents a focused play on next-generation bacterial therapeutics targeting rare and difficult-to-treat dermatological conditions.

Strategic Profile

Pro stress-test →

Azitra's pipeline includes ATR-12 for Netherton syndrome in Phase Ib trials, ATR-04 for chemotherapy-induced rash in Phase 1/2, and ATR-01 for ichthyosis vulgaris. The company has a collaboration with Bayer, which provides validation and potential commercialization support for its engineered microbiome approach.

Competitive Landscape

Pro stress-test →

Azitra competes in the niche but growing live biotherapeutic and microbiome therapeutics space, with broader dermatology competition from larger pharma (Pfizer, GSK, Abbvie) and specialized dermatology biotech. The bacterial therapeutic approach differentiates it from conventional small molecule or monoclonal antibody competitors but faces regulatory and manufacturing complexity.

Industry Context

Azitra, Inc. operates in Biotechnology - Live Biotherapeutics / Dermatology.

Key facts

Founded: 2014 · Headquarters: Branford, Connecticut, US · Employees: 12

What the analysts stress-tested

The top findings that survived the multi-agent debate for Azitra, Inc..

  • Live biotherapeutic products (genetically modified bacteria) represent differentiated approach versus traditional small molecules or biologics in dermatology
  • Extremely lean operation (12 employees) suggests capital efficiency but limits execution bandwidth and commercial capabilities
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Company traded at $0.31 as of recent data, down 3.16%, indicating market headwinds or macro pressure
  • Maintains active Phase Ib and Phase 1/2 clinical programs across dermatology franchise
Get alerted when Azitra, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Microbiome TherapeuticsEngineered microbiome and bacterial therapies for gastrointestinal and systemic conditions→Precision DermatologyTraditional small molecule and biologic treatments for skin diseases→

Compare Azitra, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Azitra, Inc. operates in Biotechnology - Live Biotherapeutics / Dermatology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Live Biotherapeutics / Dermatology research →
NEW · MCP server

Ask your AI assistant about Azitra, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Azitra, Inc. and its top competitor on Cyborg Score”
“What did Azitra, Inc. do this quarter?”
“Is Azitra, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Azitra, Inc. do?+
Azitra is an early-stage clinical biopharmaceutical company developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company represents a fo...
What is Azitra, Inc.'s Cyborg Score?+
Azitra, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Azitra, Inc.'s main competitors?+
Named competitors include Microbiome Therapeutics, Precision Dermatology. The full competitive landscape is in the AskCyborg report.
How can I get the full Azitra, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Azitra, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Azitra, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Live Biotherapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

3Seres Therapeutics, Inc.